Groupe d'Etude en Oncologie du Quebec

Title	International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer
Protocole ID	SENTICOL III
ClinicalTrials.gov ID	NCT03386734
Cancer Type(s)	Cervix
Phase	Other
Stage
Study Type	Clinical
Drug
Institution	CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE HOPITAL FLEURIMONT 3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
City
Principal Investigator	Dr. à venir
Coordinator	Annie Bourbonnais 819-346-1110 poste 12890
Status	Recruiting
Activation Date	31-05-2023
Eligibility Criteria	With squamous or adenocarcinoma of the cervix (proven by biopsy or cone biopsy), Stage Ia1 with lymphovascular emboli, Ia2, Ib1 and IIa1 (clinical stage) of the 2009 FIGO classification, Maximum diameter ≤ 40 mm by clinical examination and magnetic resonance imaging (MRI), INo suspicious node on pelvic and abdominal MRI with an exploration up to the femoralleft renal vein (according to RECIST 1.1), Eastern Cooperative Oncology Group (ECOG) Performance status 0-2, Signed informed consent and ability to comply with follow-up,
Exclusion Criteria	Pregnancy, Previous pelvic or abdominal cancer, Previous chemotherapy and/or radiation therapy for the cervical cancer (previous brachytherapy is accepted), Proven allergy to blue dye, isotope or indocyanine green (ICG).

Groupe d'étude en oncologie du Québec